The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.
ACC 2014
ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients
Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific‘s (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology’s annual meeting over the weekend.
ACC 2014 UPDATE: Reaction to Medtronic’s Symplicity renal denervation data
ACC 2014: Sapien XT bests CoreValve in small head-to-head study
UPDATED March 31, 2014, with comment from Medtronic